EMA Authorised: Edurant (rilpivirine hydrochloride) — Janssen-Cilag International N.V.

View source ↗

Summary

The EMA authorised Edurant (rilpivirine hydrochloride) for HIV infections. Decision date: 11 April 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Edurant (rilpivirine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Janssen-Cilag International N.V.. Decision date: 11/04/2025